Table 1. In Vitro and In Vivo Anti-TMV Activity of Compounds 1–34 at 500 µg/mL.
| Compd. | In vitro inhibition rate (%)a | In vivo | ||
| Inactivation effect (%)a | Curative effect (%)a | Protection effect (%)a | ||
| 1 | 47.5 | 38.5 | 31.2 | 34.3 |
| 2 | 16.5 | 20.8 | 3.9 | 12.0 |
| 3 | 33.4 | 48.4 | 3.3 | 10.1 |
| 4 | 28.7 | 45.6 | 12.6 | 22.4 |
| 5 | 68.4 | 46.6 | 38.9 | 30.8 |
| 6 | 40.5 | 34.7 | 51.7 | 32.9 |
| 7 | 29.1 | 15.1 | 24.3 | 8.9 |
| 8 | 20.6 | 10.4 | 10.3 | 11.6 |
| 9 | 26.9 | 27.0 | 10.9 | 14.7 |
| 10 | 20.4 | 23.8 | 23.8 | 8.3 |
| 11 | 25.3 | 14.8 | 15.4 | 6.0 |
| 12 | 26.8 | 20.7 | 22.1 | 28.4 |
| 13 | 30.0 | 22.9 | 21.4 | 19.3 |
| 14 | 27.5 | 23.4 | 16.8 | 20.2 |
| 15 | 0 | 0 | 0 | 8.3 |
| 16 | 18.5 | 11.1 | 10.3 | 17.2 |
| 17 | 21.3 | 19.2 | 15.2 | 18.6 |
| 18 | 17.5 | 21.9 | 19.3 | 20.4 |
| 19 | 20.0 | 13.7 | 10.2 | 15.2 |
| 20 | 52.2 | 45.0 | 46.2 | 49.7 |
| 21 | 22.3 | 17.1 | 17.5 | 21.4 |
| 22 | 36.7 | 30.1 | 33.3 | 40.2 |
| 23 | 34.4 | 21.0 | 25.3 | 30.7 |
| 24 | 42.8 | 31.3 | 37.9 | 34.4 |
| 25 | 38.3 | 31.6 | 30.0 | 28.8 |
| 26 | 34.4 | 21.0 | 25.3 | 30.7 |
| 27 | 50.4 | 48.8 | 42.5 | 46.6 |
| 28 | 27.2 | 20.8 | 38.7 | 12.5 |
| 29 | 27.1 | 11.4 | 10.8 | 6.1 |
| 30 | 23.8 | 20.0 | 20.6 | 17.3 |
| 31 | 37.5 | 30.0 | 33.3 | 32.8 |
| 32 | 31.7 | 28.9 | 27.2 | 35.4 |
| 33 | 37.6 | 33.3 | 24.6 | 31.8 |
| 34 | 45.8 | 38.9 | 40.5 | 43.2 |
| Ribavirin | 38.5 | 35.9 | 32.3 | 36.4 |
(a: For details please see Supporting Information: Text S1).